Diamond Hill Capital Management Inc. lowered its stake in Envista Holdings Co. (NYSE:NVST - Free Report) by 25.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 998,612 shares of the company's stock after selling 337,098 shares during the quarter. Diamond Hill Capital Management Inc. owned about 0.58% of Envista worth $19,263,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Swiss National Bank raised its holdings in shares of Envista by 0.8% in the fourth quarter. Swiss National Bank now owns 338,200 shares of the company's stock valued at $6,524,000 after purchasing an additional 2,800 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in shares of Envista in the fourth quarter valued at approximately $16,979,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Envista by 17.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company's stock valued at $811,000 after purchasing an additional 6,320 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Envista in the fourth quarter valued at approximately $10,808,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Envista in the fourth quarter valued at approximately $358,000.
Wall Street Analysts Forecast Growth
NVST has been the topic of a number of recent research reports. New Street Research set a $19.00 price objective on shares of Envista in a report on Thursday, March 6th. Needham & Company LLC reiterated a "hold" rating on shares of Envista in a report on Thursday, March 6th. JPMorgan Chase & Co. lowered their target price on shares of Envista from $20.00 to $19.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Morgan Stanley lowered their target price on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Finally, Mizuho initiated coverage on shares of Envista in a report on Wednesday, December 4th. They set an "underperform" rating and a $20.00 target price on the stock. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $20.18.
Check Out Our Latest Research Report on Envista
Envista Stock Performance
NVST stock traded up $0.12 during midday trading on Wednesday, reaching $17.02. 1,852,025 shares of the company were exchanged, compared to its average volume of 2,283,402. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The business has a 50-day moving average price of $19.89 and a two-hundred day moving average price of $19.63. Envista Holdings Co. has a one year low of $15.15 and a one year high of $23.00. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -2.62, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.
Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts forecast that Envista Holdings Co. will post 1 EPS for the current year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
